ArticlemBio2017
Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Natural products shape microbial ecology and disease in the cystic fibrosis airway.Natural product reports · 2026Review
- Silibinin Potentiates Antimicrobial Action and Reduces Staphyloxanthin inPharmaceuticals (Basel, Switzerland) · 2026Article
- Clemizole inhibits CrtN-driven staphyloxanthin biosynthesis in Staphylococcus aureus to enhance host immune clearance.Communications biology · 2026Article
- Strategies for Survival ofInternational journal of molecular sciences · 2025Review
- The anti-biofilm compound 4-ethoxybenzoic acid inhibitsFrontiers in microbiology · 2025Article
- YTHDF2-mediated mFrontiers in cellular and infection microbiology · 2025Article
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- Unveiling the impact of selected essential oils on MRSA strain ATCC 33591: antibacterial efficiency, biofilm disruption, and staphyloxanthin inhibition.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- In silico investigation of cholesterol-lowering drugs to find potential inhibitors of dehydrosqualene synthase in3 Biotech · 2024Article
- The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity.RSC medicinal chemistry · 2024Article
- Investigating the effect ofIn silico pharmacology · 2024Article
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Staphylococcus aureus host interactions and adaptation.Nature reviews. Microbiology · 2023Review
- Identification of a Small Molecule Compound Active against Antibiotic-TolerantInternational journal of molecular sciences · 2023Article
- Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach.BMC microbiology · 2022Article
- Staphyloxanthin as a Potential Novel Target for Deciphering Promising Anti-Antibiotics (Basel, Switzerland) · 2022Review
- Small-molecule compound SYG-180-2-2 attenuatesFrontiers in cellular and infection microbiology · 2022Article
- Article
- Measurement of Staphylococcus aureus Pigmentation by Methanol Extraction.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Carvacrol Targets SarA and CrtM of Methicillin-ResistantACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.